Picture loading failed.

Anti-VEGFA therapeutic antibody (Pre-made Varisacumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Varisacumab (GNR 011), a biosimilar of bevacizumab [see Adis Insight Drug profile 800008086] is under development with International Biotech Center Generium (IBC Generium), for the treatment of various types of cancer, including colorectal, non-small cell lung, glioblastoma and breast cancer, and ophthalmic conditions.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-613-1mg 1mg 3090
GMP-Bios-ab-613-10mg 10mg 21890
GMP-Bios-ab-613-100mg 100mg 148000
GMP-Bios-ab-613-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-VEGFA therapeutic antibody (Pre-made Varisacumab biosimilar,Whole mAb)
INN Name Varisacumab
TargetVEGFA
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II/III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesPeregrine Pharmaceuticals;University of Texas Southwestern Medical Center;Affitech Research AS
Conditions Approvedna
Conditions ActiveBreast cancer;Colorectal cancer;Eye disorders;Glioblastoma;Non-small cell lung cancer
Conditions Discontinuedna
Development Techna